• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 8th August 2018

Opportunity Costs of New Health Care Technologies: A Research Agenda

A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS. For many years, health economists have been concerned with the development of methods for the estimation of cost-effectiveness thresholds.…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.

For many years, health economists have been concerned with the development of methods for the estimation of cost-effectiveness thresholds. Yet in numerous cases, thresholds are used without an apparent evidence base. In a new OHE Research Paper, Karla Hernandez-Villafuerte (German Cancer Research Center, DKFZ), Bernarda Zamora and Adrian Towse set out a research agenda.

The authors propose new approaches in three areas to improve understanding of supply-side opportunity costs for the English NHS.

First, it is possible that some purchasers can introduce health services by improving efficiency rather than displacing an existing activity. Data Envelopment Analysis (DEA) can be used to explore differences in commissioner efficiency.

Second, health authorities (PCTs) have differences in their production functions. The paper sets out evidence of this from a cluster analysis of PCTs. Purchasers may displace those services with relatively smaller health losses. Current approaches estimate the relationship between expenditures and health outcomes using a linear regression methodology. However, if health locations are heterogeneous, a methodology that does not focus on the mean is preferable. One possible approach is to employ a quantile regression function which can accommodate non-linearity in the relationship between expenditures and outcomes, and variation in outcome elasticities at the margin.

Thirdly, there are observable health outcomes reflecting purchaser priorities other than reducing mortality. Use of DEA to analyse multi-outcome decisions will allow a more robust estimate of the cost-effectiveness threshold given the sources of local heterogeneity.

The proposed methods aim at gaining insight into the extent of heterogeneity in supply-side opportunity costs across English health services and how an estimate of a supply-side threshold that takes account of this might be established.

Citation

Hernandez-Villafuerte, K., Zamora, B., and Towse, A. 2018. Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology. OHE Research Paper 18/07, London: Office of Health Economics. RePEc

Related research

Barnsley, P., Towse, A., Karlsberg Schaffer, S. and Sussex, J. 2013. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold. OHE Occasional Paper. RePEc

Karlsberg Schaffer, S., Cubi-Molla, P., Devlin, N. and Towse, A. 2016. Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making. OHE Consulting Report. RePEc

Danzon, P.M., Drummond, M.F., Towse, A. and Pauly, M.V. 2018. Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4]. Value in Health 21(2), 140-145. DOI

 

  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!